No Data
No Data
No Data
No Data
No Data
Dynacure Receives Fast Track Designation for DYN101, an Investigational Antisense Oligonucleotide for the Treatment of Myotubular and Centronuclear Myopathies
STRASBOURG, Pa., Jan. 6, 2022 /PRNewswire/ -- Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S.
PR NewswireJan 6, 2022 16:12 ET
Dynacure to Present at 40th Annual J.P. Morgan Healthcare Conference
STRASBOURG, France and PHILADELPHIA, Jan. 3, 2022 /PRNewswire/ -- Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating and life-threatening genetic diseases, today anno
PR NewswireJan 3, 2022 16:12 ET
BRIEF-Dynacure Announces Strategic Collaboration And Option Agreement With Nippon Shinyaku
Nov 10 (Reuters) - Dynacure Sa DYCU.O :* DYNACURE ANNOUNCES STRATEGIC COLLABORATION AND OPTION AGREEMENT WITH NIPPON SHINYAKU* NIPPON SHINYAKU SECURES AN EXCLUSIVE OPTION TO ACQUIRE ALL DEVELOPMENT A
reutersNov 10, 2021 03:06 ET
NASDAQ TRADE HALT DYCU.O REASON NOT AVAILABLE AT 04:00 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 A
路透社Jul 14, 2021 04:00 ET
No Data
No Data
thamwh19 : Good
Kenji Leow KC : wow
steady Pom pipi :